ACTON, Mass. — Insulet Corp. reported a sharp increase in first-quarter revenue and raised its full-year revenue guidance, citing continued growth for its Omnipod insulin pump products and expanding international availability.
The Acton-based company, which makes tubeless insulin pump technology under the Omnipod brand, reported revenue of $761.7 million for the quarter ended March 31, up 33.9% from a year earlier. Revenue rose 30.1% on a constant-currency basis and exceeded the high end of the company’s previous guidance range.
Total Omnipod revenue increased 36.9% to $758.4 million, or 33% on a constant-currency basis. U.S. Omnipod revenue rose 28.3% to $515.6 million, while international Omnipod revenue increased 59.4% to $242.9 million, or 45.2% on a constant-currency basis. Drug Delivery revenue was $3.3 million.
Insulet reported operating income of $122.1 million, representing 16% of revenue and up 40 basis points from the prior year. Adjusted operating income was $133.5 million, or 17.5% of revenue, up 110 basis points from a year earlier.
Net income was $91.1 million, or $1.30 per diluted share, compared with $35.4 million, or 50 cents per diluted share, in the same period last year. Adjusted net income was $99.8 million, or $1.42 per diluted share, compared with $73.7 million, or $1.02 per diluted share, a year earlier.
The company said it launched Omnipod 5 and Omnipod Discover in five countries in the Middle East, bringing Omnipod 5 availability to 19 countries. Insulet also presented data at the Advanced Technologies & Treatments for Diabetes International Conference on an Omnipod 5 algorithm update following a limited market release. The update is expected to launch more broadly in the coming weeks and is designed to improve automation and performance, including a new 100 mg/dL target glucose setting and changes aimed at reducing interruptions during extended high-glucose events.
Insulet also completed a U.S. limited market release of the Omnipod 5 algorithm with FreeStyle Libre 3 Plus, broadening sensor connectivity across major continuous glucose monitoring platforms.
The company said it reached milestones in developing a fully closed-loop automated insulin delivery system for adults with type 2 diabetes. Insulet presented data from its EVOLUTION 2 trial and enrolled the first participant in the EVOLVE pivotal study, which is intended to support a 510(k) filing in 2027.
During the quarter, Insulet also repurchased 1.25 million shares of common stock and released its 2025 Sustainability Report.
“We started the year strong, delivering continued growth momentum and robust operating margin expansion in the first quarter,” said Ashley McEvoy, President and CEO. “Our team executed on our strategic priorities, growing our global Podder community and strengthening our leadership in the AID market, and we are raising our total company revenue growth outlook to reflect our progress. We are confident in our ability to achieve our long-term growth objectives by accelerating innovation, developing our markets, strengthening our commercial engine, and scaling our global operations.”
